Scarica l'app Stockscreener
15.22
0.13%
0.02
Dopo l'orario di chiusura:
15.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$15.20
Aprire:
$15.31
Volume 24 ore:
1.80M
Relative Volume:
1.43
Capitalizzazione di mercato:
$2.60B
Reddito:
-
Utile/perdita netta:
$-382.71M
Rapporto P/E:
-5.8092
EPS:
-2.62
Flusso di cassa netto:
$-325.64M
1 W Prestazione:
-1.55%
1M Prestazione:
-12.98%
6M Prestazione:
-25.14%
1 anno Prestazione:
-50.71%
Intervallo 1D:
$14.98
$15.31
Intervallo di 1 settimana:
$14.32
$16.18
Portata 52W:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
15.22 | 2.65B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
How to recover losses in Immunovant Inc. stockJuly 2025 Retail & Risk Managed Investment Signals - Newser
Immunovant Inc. stock trendline breakdownQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser
Key metrics from Immunovant Inc.’s quarterly dataJuly 2025 Market Mood & High Yield Equity Trading Tips - Newser
Full technical analysis of Immunovant Inc. stockEarnings Overview Report & Growth Focused Entry Point Reports - Newser
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus - MSN
Technical Bounce Expected in Immunovant Inc. Next WeekDividend Hike & Weekly Setup with High ROI Potential - thegnnews.com
Immunovant, Inc. shares fall 3.83% intraday after law firm investigation announcement. - AInvest
Immunovant shares fall 5.54% premarket after law firm investigation announcement. - AInvest
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.IMVT - Business Wire
Immunovant Reports Progress and Financial Results - TipRanks
Immunovant price target lowered to $57 from $58 at Citi - MSN
Chart based exit strategy for Immunovant Inc.Trade Analysis Report & Verified Swing Trading Watchlist - Newser
Immunovant (NASDAQ:IMVT) Price Target Cut to $30.00 by Analysts at Bank of America - Defense World
Immunovant (NASDAQ:IMVT) Given New $37.00 Price Target at JPMorgan Chase & Co. - Defense World
Immunovant Receives Buy Rating from Guggenheim with $44 Price Target - AInvest
IMVT: Analyst Jason Gerberry Lowers Price Target to $30, Maintains 'Buy' Rating - AInvest
Immunovant's Q1 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Chart Patterns Forming a Bullish Setup in Immunovant Inc.Reliable Investment Entry Signals Confirmed by Charts - sundaytimes.kr
What makes Immunovant Inc. stock price move sharplyWealth Tripler Trade List - newsyoung.net
Why Immunovant Inc. stock attracts strong analyst attentionSmart Money Strategy for Growth Stocks - Newser
Immunovant Spends More To Move Key Drug Trials Forward - Finimize
Immunovant Pours More Into Trials And Investors Aren’t Flinching - Finimize
Immunovant Posts 34% R&D Jump in Q1 - AOL.com
Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy - Investing.com Canada
Assessing Immunovant's Strategic Expansion and Financial Viability Amid Widening Losses - AInvest
Immunovant's Fiscal Q1 Net Loss Widens - MarketScreener
Immunovant Posts 34% R&D Jump in Q1 - The Motley Fool
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
Immunology company Immunovant's Q1 net loss widens to $120.6 mln - MarketScreener
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 - The Manila Times
Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News - Stock Titan
Candlestick Reversal Detected on Immunovant Inc.’s ChartReal Time Alerts Based on AI Prediction Triggered - metal.it
Combining price and volume data for Immunovant Inc.Free Investment Strategy With Predictable Gains - Newser
Pattern recognition hints at Immunovant Inc. upsideFree Weekly Growth Stock Entry Point Alerts - Newser
Immunovant Inc. Company Revenue and Profit Trends: A Deep DiveTechnical Analysis of Growth Stock Opportunities - Newser
Is Immunovant Inc. a growth stock or a value stockStrong return on investment - Jammu Links News
How does Immunovant Inc. compare to its industry peersAchieve rapid portfolio appreciation today - Jammu Links News
What are the technical indicators suggesting about Immunovant Inc.Massive wealth growth - Jammu Links News
Is Immunovant Inc. a good long term investmentFastest-growing stock picks - Jammu Links News
Should I hold or sell Immunovant Inc. stock in 2025Sky-high return potential - Jammu Links News
When is Immunovant Inc. stock expected to show significant growthTriple-digit growth rates - Jammu Links News
How volatile is Immunovant Inc. stock compared to the marketUnmatched market gains - Jammu Links News
What drives Immunovant Inc. stock priceCapitalize on market opportunities with confidence - Jammu Links News
What institutional investors are buying Immunovant Inc. stockOutperformance with explosive growth - Jammu Links News
Is it the right time to buy Immunovant Inc. stockFree Stock Movement Tracking - Jammu Links News
What catalysts could drive Immunovant Inc. stock higher in 2025Breakthrough wealth creation - Jammu Links News
Immunovant (IMVT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Is Immunovant Inc. stock overvalued or undervaluedBuild a portfolio that outperforms the market - Jammu Links News
What are analysts’ price targets for Immunovant Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
How does Immunovant Inc. generate profit in a changing economyFree Capital Growth Strategies - Jammu Links News
What analysts say about Immunovant Inc. stockCapitalize on market momentum for big wins - Jammu Links News
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):